Clinical trials: Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
Kidney Cancer, Melanoma (Skin)
Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial
RATIONALE: Diagnostic procedures, such as positron emission tomography and computed tomography scan (done before and after cellular adoptive immunotherapy), may help doctors predict a patient's response to treatment and help plan…
- Trial name
- NCT00316901
- Testing
- computed tomography, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
New AI-based Technologies in Nuclear Medicine
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring.
- Trial name
- AI-basedMedNuc (NCT07174089)
- Testing
- RadEye SPRD-ER device: spectrometric radiation detector capable of detecting gamma radiation.
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Lung Cancer, Metastatic Cancer
Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35
RATIONALE: Diagnostic procedures, such as positron emission tomography and computed tomography, may help learn the extent of disease and allow doctors to plan 3-dimensional conformal radiation therapy.
- Trial name
- NCT00958321
- Testing
- computed tomography, 3-dimensional conformal radiation therapy, fludeoxyglucose F 18
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Cancer Trials Ireland